Editors:
- Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field
- Traces all aspects of HCV research that contributed to the development of key drugs and to the identification of important drug
- Provides an authoritative history of the journey to find a cure for HCV with accounts from the key researchers themselves
Part of the book series: Topics in Medicinal Chemistry (TMC, volume 31)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (17 chapters)
-
Front Matter
-
The Virus & Early Therapy
-
Front Matter
-
-
HCV NS5B Polymerase Inhibitors
-
Front Matter
-
-
HCV NS3/4a Protease Inhibitors
-
Front Matter
-
About this book
This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".
Editors and Affiliations
-
Arbutus Biopharma, Inc., Warminster, USA
Michael J. Sofia
About the editor
Michael J. Sofia, Ph.D. is currently Chief Scientific Officer and co-founder at Arbutus Biopharma, Inc., a company focused on the discovery and development of therapies to treat hepatitis B. He also holds a professorship at the Baruch S. Blumberg Institute and an Adjunct Professorship at the Drexel University School of Medicine.
Previously, Mike Sofia was Senior Vice President of Chemistry and Senior Advisor at Gilead Sciences and was Sr. Vice President of Chemistry at Pharmasset, Inc until Pharmasset’s acquisition by Gilead in Jan 2012.
Mike Sofia previously held research and research management positions at Bristol-Myers Squibb, Intercardia Research Labs (formerly Transcell Technologies) and Eli Lilly & Co. He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University and received his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign. He earned his B.A. degree in chemistry from Cornell University.
Mike has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He is the principle inventor of sofosbuvir (Sovaldiâ and Harvoniâ) currently marketed as a treatment for the cure of HCV infection. Mike is the recipient of numerous awards including the 2015 ACS Heroes of Chemistry Award, the Economist Magazine’s 2015 Innovation Award in Biosciences, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research and the 2017 Gertrude Elion Award from the International Society for Antiviral Research.
Bibliographic Information
Book Title: HCV: The Journey from Discovery to a Cure
Book Subtitle: Volume I
Editors: Michael J. Sofia
Series Title: Topics in Medicinal Chemistry
DOI: https://doi.org/10.1007/978-3-030-28207-3
Publisher: Springer Cham
eBook Packages: Chemistry and Materials Science, Chemistry and Material Science (R0)
Copyright Information: Springer Nature Switzerland AG 2019
Hardcover ISBN: 978-3-030-28206-6Published: 03 December 2019
Softcover ISBN: 978-3-030-28209-7Published: 16 December 2020
eBook ISBN: 978-3-030-28207-3Published: 23 November 2019
Series ISSN: 1862-2461
Series E-ISSN: 1862-247X
Edition Number: 1
Number of Pages: VIII, 463
Number of Illustrations: 1 b/w illustrations
Topics: Medicinal Chemistry, Virology, Medical Biochemistry, Bioorganic Chemistry, Pharmaceutical Sciences/Technology